TENX Tenax Therapeutics, Inc. - 8-K

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 2, 2026, Tenax Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following proposals were voted upon at the Annual Meeting and the final voting results with respect to each such proposal are set forth below.

Proposal 1: Election of Directors

The Company’s stockholders elected each of the following individuals to the Company’s Board of Directors for a one-year term expiring in 2027, or until his or her successor is duly elected and qualified, by the votes indicated below.

Members

For

Withheld

Broker Non-Votes

June Almenoff

17,362,177

214,449

3,742,678

Michael Davidson

15,762,162

1,814,464

3,742,678

Declan Doogan

17,394,626

182,000

3,742,678

Christopher T. Giordano

17,397,265

179,361

3,742,678

Robyn M. Hunter

17,394,848

181,778

3,742,678

Gerald T. Proehl

17,393,189

183,437

3,742,678

Stuart Rich

17,397,413

179,213

3,742,678

Proposal 2: Auditor Ratification

The Company’s stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the votes indicated below.

For

Against

Abstain

Broker Non-Votes

21,304,543

3,688

11,073

None